⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S4 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

Anthony W. Tolcher Joshua Brody Nishanthan Rajakumaraswamy Michelle Kuhne Torsten Trowe Anees M. Dauki Shantheri Pai Ling Han Kai-Wen Lin Michael Petrarca Shivaani Kummar

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Spaghetti plots of A. neutrophils and B. monocytes by dose.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tolcher et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db64358752382f https://doi.org/10.1158/1078-0432.27034462

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024
2Supplementary Figure S2 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024
3Supplementary Figure S2 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024
4Supplementary Figure S3 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024
5Supplementary Figure S3 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors2024